No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
JELD240719C15000
- 0.10
- -0.30-75.00%
15min DelayClose Jul 2 10:13 ET
0.10High0.10Low
0.10Open0.40Pre Close2 Volume396 Open Interest15.00Strike Price20.00Turnover58.08%IV16.96%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier16DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.1307Delta0.1321Gamma129.10Leverage Ratio-0.0103Theta0.0007Rho16.88Eff Leverage0.0059Vega
Intraday
- 5D
- Daily
News
JELD-WEN to Release Second Quarter 2024 Results
JELD-WEN Holding, Inc. (NYSE: JELD), a leading global manufacturer of building products, announced today that it will release second quarter 2024...
Pool Hits 8-month Low on Revised Guidance; Suppliers of Building Materials Sell off
JELD-WEN Holding Chief Financial Officer to Step Down at End of June
JELD-WEN Holding (JELD) said late Monday that Julie Albrecht will step down as chief financial officer, effective June 30. Samantha Stoddard, who currently serves as JELD-WEN North America CFO and hea
Patterson Companies, KB Home And Other Stocks To Watch This Tuesday
With U.S. stock futures trading mixed this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:Wall Street expects Patterson Companies, Inc. (NASDAQ:PDCO) to repor
Express News | JELD-WEN Holding Inc: Stoddard Will Succeed Julie C. Albrecht
Express News | JELD-WEN Names Samantha L. Stoddard Chief Financial Officer
Comments
The trend of lower returns on the same capital suggests it's not a growth stock. The declining ROCE and stagnant capital employed could indicate a mature business facing new competition or smaller margins.
The Returns On Capital At JELD-WEN Holding (NYSE:JELD) Don't Inspire Confidence 1
Insider selling at JELD-WEN Holding, even below the current price, may worry investors. The absence of insider buying in the past year doesn't convey optimism about the stock. Yet, moderate insider ownership shows some alignment between management and smaller shareholders.
JELD-WEN's ROE is below industry average and its high debt levels could signal risk. The company's reliance on debt to boost ROE is less satisfactory due to its sub-par returns.
JELD-WEN Holding's stable ROCE suggests a mature operation without promising substantial growth. The stock's 41% decline over five years questions the prospect for these trends to improve soon, making the company a less attractive option for potential multi-bagger returns.
Gapping up
In reaction to earnings/guidance:
• $ChargePoint(CHPT.US$ +2.8%, $Designer Brands(DBI.US$ +1.8%, $Donaldson(DCI.US$ +0.7%
Other news:
• $Cepton(CPTN.US$ +9.2% (receives non-bindingLolfor a $100mln investment from Koito Manufacturing)
• $Sorrento Therapeutics(SRNE.US$ +7.2% (receives FDA Fast Track Designation for SP-103(Lidocaine Topical System) 5.4%)
• $Mereo BioPharma(MREO.US$ +6.7% (sends letter to Rubric Capital...
In reaction to earnings/guidance:
• $ChargePoint(CHPT.US$ +2.8%, $Designer Brands(DBI.US$ +1.8%, $Donaldson(DCI.US$ +0.7%
Other news:
• $Cepton(CPTN.US$ +9.2% (receives non-bindingLolfor a $100mln investment from Koito Manufacturing)
• $Sorrento Therapeutics(SRNE.US$ +7.2% (receives FDA Fast Track Designation for SP-103(Lidocaine Topical System) 5.4%)
• $Mereo BioPharma(MREO.US$ +6.7% (sends letter to Rubric Capital...
9
Read more